Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...

J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...

In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the Phase 2b JASMINE trial for systemic lupus erythematosus and moved the program ...

Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...

Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...

Johnson & Johnson said it will initiate a Phase 3 trial of its treatment for systemic lupus erythematosus, or SLE, after a recent study of the therapy met its primary endpoint.

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...